Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy
Key Clinical Message There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B‐ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.8289 |
| _version_ | 1827395297450393600 |
|---|---|
| author | Si‐Man Huang Chao‐Ling Wan Han‐Yu Cao Yan‐Yan Li Chong‐Sheng Qian Hai‐Xia Zhou Ming‐Zhu Xu Xiao‐Hui Hu Lan Dai Hai‐Ping Dai Sheng‐Li Xue |
| author_facet | Si‐Man Huang Chao‐Ling Wan Han‐Yu Cao Yan‐Yan Li Chong‐Sheng Qian Hai‐Xia Zhou Ming‐Zhu Xu Xiao‐Hui Hu Lan Dai Hai‐Ping Dai Sheng‐Li Xue |
| author_sort | Si‐Man Huang |
| collection | DOAJ |
| description | Key Clinical Message There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B‐ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy. |
| first_indexed | 2024-03-08T18:31:09Z |
| format | Article |
| id | doaj.art-e00f4ab4696542c7889d7aed2a24ad24 |
| institution | Directory Open Access Journal |
| issn | 2050-0904 |
| language | English |
| last_indexed | 2024-03-08T18:31:09Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical Case Reports |
| spelling | doaj.art-e00f4ab4696542c7889d7aed2a24ad242023-12-30T04:35:09ZengWileyClinical Case Reports2050-09042023-12-011112n/an/a10.1002/ccr3.8289Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapySi‐Man Huang0Chao‐Ling Wan1Han‐Yu Cao2Yan‐Yan Li3Chong‐Sheng Qian4Hai‐Xia Zhou5Ming‐Zhu Xu6Xiao‐Hui Hu7Lan Dai8Hai‐Ping Dai9Sheng‐Li Xue10National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou ChinaKey Clinical Message There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B‐ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.https://doi.org/10.1002/ccr3.8289B‐ALLCD22inotuzumab ozogamicinMRD positiverelapsed and refractory |
| spellingShingle | Si‐Man Huang Chao‐Ling Wan Han‐Yu Cao Yan‐Yan Li Chong‐Sheng Qian Hai‐Xia Zhou Ming‐Zhu Xu Xiao‐Hui Hu Lan Dai Hai‐Ping Dai Sheng‐Li Xue Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy Clinical Case Reports B‐ALL CD22 inotuzumab ozogamicin MRD positive relapsed and refractory |
| title | Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy |
| title_full | Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy |
| title_fullStr | Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy |
| title_full_unstemmed | Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy |
| title_short | Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy |
| title_sort | preemptive inotuzumab ozogamicin eradicated measurable residual disease in ph negative acute lymphoblastic leukemia relapsed post cd19 cart therapy |
| topic | B‐ALL CD22 inotuzumab ozogamicin MRD positive relapsed and refractory |
| url | https://doi.org/10.1002/ccr3.8289 |
| work_keys_str_mv | AT simanhuang preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy AT chaolingwan preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy AT hanyucao preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy AT yanyanli preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy AT chongshengqian preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy AT haixiazhou preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy AT mingzhuxu preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy AT xiaohuihu preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy AT landai preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy AT haipingdai preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy AT shenglixue preemptiveinotuzumabozogamicineradicatedmeasurableresidualdiseaseinphnegativeacutelymphoblasticleukemiarelapsedpostcd19carttherapy |